证券代码：836433 证券简称：大唐药业 公告编号：2025-064 内蒙古大唐药业股份有限公司董事、高级管理人员离职管 理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 第三条 董事、高级管理人员候选人的任职资格应当符合法律法规、北京证 券交易所业务规则和《公司章程》等规定。存在下列情形之一的，不得担任公司 董事或者高级管理人员： 一、 审议及表决情况 内蒙古大唐药业股份有限公司于 2025 年 8 月 25 日召开第四届董事会第五次 会议，审议通过《关于制定及修订公司内部管理制度的议案》之子议案《制定< 董事、高级管理人员离职管理制度>》，议案表决结果：同意 7 票；反对 0 票；弃 权 0 票。该议案无需提交股东会审议。 二、 分章节列示制度主要内容： 第一章 总则 第一条 为规范内蒙古大唐药业股份有限公司（以下简称"公司"）董事、 高级管理人员离职程序，确保公司治理结构的稳定性和连续性，维护公司及股东 的合法权益，公司根据《中华人民共和国公司法》（以下简称《公司法》）《上 市公司章程指引 ...

证券代码：836433 证券简称：大唐药业 公告编号：2025-041 内蒙古大唐药业股份有限公司关联交易管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 内蒙古大唐药业股份有限公司于 2025 年 8 月 25 日召开第四届董事会第五次 会议，审议通过《关于制定及修订公司内部管理制度的议案》之子议案《修订< 关联交易管理制度>》，议案表决结果：同意 7 票；反对 0 票；弃权 0 票。该议案 尚需提交股东会审议。 二、 分章节列示制度主要内容： 第一章 总则 第一条 为进一步规范内蒙古大唐药业股份有限公司（以下简称"公司"） 关联交易行为，保证关联交易的公允性，切实保护投资者的利益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《北京证券交易所上市公司持续监管 办法（试行）》（以下简称"《监管办法》"）《北京证券交易所股票上市规则》（以 下简称"《上市规则》"）等有关法律、法规以及《内蒙古大唐药业股份有限公司 章程》（以下简称"《公司章程》"）的规定，结合公司的实 ...

证券代码：836433 证券简称：大唐药业 公告编号：2025-042 内蒙古大唐药业股份有限公司承诺管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 内蒙古大唐药业股份有限公司于 2025 年 8 月 25 日召开第四届董事会第五次 会议，审议通过《关于制定及修订公司内部管理制度的议案》之子议案《修订< 承诺管理制度>》，议案表决结果：同意 7 票；反对 0 票；弃权 0 票。该议案尚需 提交股东会审议。 二、 分章节列示制度主要内容： 第一章 总则 第一条 为加强内蒙古大唐药业股份有限公司（以下简称"公司"）控股股 东、实际控制人、董事、高级管理人员、关联方、收购人（以下合称"承诺相关 方"）及公司的承诺管理，切实保护中小投资者合法权益，根据《中华人民共和 国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证 券法》"）《北京证券交易所上市公司持续监管办法（试行）》《北京证券交易所股 票上市规则》等有关法律法规、部门规章、规范性文件及《内蒙古大唐 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies [36]. Core Insights - The aerospace and drone sectors are highlighted as potential catalysts for investment opportunities [3]. - The military industry sector showed significant performance, with notable stock increases for companies like Xingchen Technology (15.9%) and Tongyi Aerospace (7.0%) [3][17]. - The report emphasizes the ongoing interest in innovative pharmaceuticals, AI hardware technology iterations, and new production capabilities, driven by policy benefits and industrial capital [3]. - The North Exchange is expected to strengthen its investment value due to policy-driven and fundamental improvements as more quality companies list on the exchange [3]. Summary by Sections Market Review - On August 4, the North Exchange A-share trading volume reached 19.81 billion yuan, a decrease of 1.92 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1433.25, up 0.96% [7][15]. - The North Exchange specialized index closed at 2460.21, increasing by 1.42% [7]. Stock Performance - Among the 269 companies on the North Exchange, 158 saw stock price increases, 4 remained flat, and 107 experienced declines [17]. - The top five gainers included Xingchen Technology (15.9%), Tongyi Aerospace (7.0%), and Sanyuan Gene (6.9%) [17][19]. - The top five decliners included Shengtong Valley (-8.5%), Dingjia Precision (-4.9%), and Datang Pharmaceutical (-4.9%) [17][19]. Important News - Significant progress was reported in the development of an AIDS vaccine in China, marking a milestone in the field [20]. - Shanghai's government is promoting the inclusion of more companies in integrated circuits, biomedicine, and artificial intelligence sectors under the "Explorer Program" [21]. Key Company Announcements - Huitong New Materials reported a revenue of 112 million yuan for the first half of 2025, a year-on-year increase of 8.37%, with a net profit of 24 million yuan, up 27.58% [22]. - Guanzhi International announced a revenue of 247 million yuan for the first half of 2025, reflecting a 5.20% year-on-year growth, with a net profit of 46 million yuan, up 7.12% [29].

(责任编辑：宋政 HN002) 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷涨近25%，维康药业20CM涨停，新光药业 (300519)涨13%，大唐药业涨近11%，天目药业(600671)、新天药业(002873)、太龙药业(600222)、奇正 藏药(002287)、贵州百灵(002424)10CM涨停，众生药业(002317)涨超8%，亚宝药业(600351)、沃华医药 (002107)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76亿 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10. ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷（维权）涨近25%，维康药业（维权）20CM 涨停，新光药业涨13%，大唐药业涨近11%，天目药业、新天药业、太龙药业、奇正藏药、贵州百灵 （维权）10CM涨停，众生药业涨超8%，亚宝药业、沃华医药（维权）涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76 乙 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10.03 | 29.19亿 | 27.68 | | 600222 | 太龙药业 | 10.00 | 39.14 ...

（文章来源：每日经济新闻） 每经AI快讯，8月1日，午后中药板块持续逆势拉升，天目药业、华森制药涨停，生物谷一度触及30%涨 停，新光药业、大唐药业涨超10%，亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...

Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]

证券时报·数据宝统计，截至今日上午10:29，上证综指3576.84点，收于五日均线之下，涨跌幅0.10%， A股总成交额为7270.04亿元。到目前为止，今日有665只A股价格突破了五日均线，其中乖离率较大的 个股有生物谷、启迪设计、捷佳伟创等，乖离率分别为16.03%、14.73%、12.98%；亿道信息、王子新 材、派克新材等个股乖离率较小，刚刚站上五日均线。 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 833266 | 生物谷 | 22.10 | 18.16 | 11.95 | 13.87 | 16.03 | | 300500 | 启迪设 计 | 20.00 | 12.63 | 14.02 | 16.08 | 14.73 | | 300724 | 捷佳伟 创 | 20.00 | 16.10 | 58.59 | 66.19 | 12.98 | | 688680 | 海优新 材 | ...

Group 1: Investor Relations Activity - The investor relations activity was held on July 11, 2025, from 16:00 to 18:00 via an online platform [3] - Participants included the company's Vice Chairman and Secretary of the Board, Ms. Sun Yali, and Financial Officer, Mr. Wu Bo [3] Group 2: Research and Development Progress - The company has established a three-tiered R&D system with 2 national projects, 3 regional key projects, and 3 municipal key projects [4] - The company is enhancing its intellectual property protection and has formed partnerships with several universities and research institutions to advance the modernization of traditional Chinese medicine [4] Group 3: Future Planning and Strategy - The company is focusing on a "123" overall development strategy centered on traditional Mongolian medicine, with a focus on specialty drugs and health products [5] - The strategy includes integrating financial capital, marketing resources, and R&D efforts to support sustainable growth [5] Group 4: Product Development Update - The company completed the filing for the "An Gong Niu Huang Wan" product on February 7, 2024, with modifications to its formula [6] - The financial impact of this product on the company's results remains uncertain, and investors are advised to be cautious [6] Group 5: Financial Performance - The company plans to disclose its half-year report on August 27, 2025, which will provide insights into its operational performance [8]